참고문헌
- Bourne DWA, 2002. Pharmacokinetics. In: Banker G.S., Rhodes C.T., Modern Pharmaceutics, 4th ed., marcel Dekker Inc., New York, 67-92.
- Buzelin, J.M., Hebert, M., Blondin, P., te Prazalf Group, 1993. Alpha blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin, Br. J. Urol. 72, 922-927. https://doi.org/10.1111/j.1464-410X.1993.tb16298.x
- Costa, P., Lobo, J., 2001. Modeling and comparison of dissolution profile, Eur. J. Pharm. 13, 123-133. https://doi.org/10.1016/S0928-0987(01)00095-1
- Hadjiioannou, T.P., Christian, G.D., Koupparis, M.A., Macheras, P.E., 1993. Quantitative Calculations in Pharmaceutical Practice and Reserarch, VCH Publishers inc., New York, 345-348.
- Higuchi, T., 1963. Mechanism of sustained action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm.Sci., 52, 1145-1149. https://doi.org/10.1002/jps.2600521210
- Hixson, A.W., Crowell, J.H., 1931. Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind. Eng. Chem., 23, 923-931. https://doi.org/10.1021/ie50260a018
- Jardin, A.H., Bensadoun, H., Delauche-Cavaller, M.C., Attali, P., The BPH-ALF Group, 1993. Long term treatment of benign prostatic hypertropy with alfuzosin: a 12-18 month assessment. ., 72, 615-620. https://doi.org/10.1111/j.1464-410X.1993.tb16220.x
- Jardin, A.H., Bensadoun, H., Delauche-Cavaller, M.C., Attali, P., The BPH-ALF Group, 1999. Long term treatment of benign prostatic hypertropy with alfuzosin: a 24-30 month survey. Br. J. Urol. 74, 579-584. https://doi.org/10.1111/j.1464-410X.1994.tb09187.x
- Jardin, A.H., Bensadoun, H., Delauche-Cavaller, M.C.., Attali, P., The BPH-ALF Group, 1991. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337, 1457-1461. https://doi.org/10.1016/0140-6736(91)93140-5
- JENN-CHIANG MACHINERY Homepage http://www.jcmco.com.tw/ dh.htm
- Korsmeyer, R.W., Gurny, R., Doelker, E., Buri, P., Peppas, N.A., 1983. Mechanisms of solute release from porous hydrophilic polymers. Int. J. pharm., 15, 25-35. https://doi.org/10.1016/0378-5173(83)90064-9
- Maggi, L., Conte, U., Grenier, P., Vergnault, G., Dufour, A., Jarreau, F.X., Rauch-Desant, C., 2000. Tablet with controlled release of alfuzosine chlorhydrate, US Patent 6, 149,940.
- Moore, J.W., Flanner, H.H., 1996. Mathematical comparison of dissolution profile, Pharm. Tech. 20, 64-74.
- Shoaib, M.H., Tazeen, J., Merchant, H.A., Yousuf, R.I., 2006. Evaluation of drug release kinetics from Ibuprofen matrix tablet using HPMC. Pak. J. Pharm. Sci., 19, 119-124.
- Tahara, K., Yamamoto, K., Nishihata, T., 1995. Overall mechanism behind matrix sustained release (SR) tablet prepared with hydroxypropyl methylcellulose 2910, J. Control. Release 35, 59-66. https://doi.org/10.1016/0168-3659(95)00021-Y
- Teillac, P., Delauche-Cavallier, M.C., Attali, P., The Dualf Group, 1992. Urinary flow assessment after a single oral administration of alfuzosin, a new alpha1, blocker, in patients with benign prostatic hypertrophy, Br. J. Urol. 70, 58-64. https://doi.org/10.1111/j.1464-410X.1992.tb15665.x
- Vueba, M.L., Batista, de Carvalho, L.A.E., Veiga, F., Sousa, J.J., Pina, M.E., 2004. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets, Eur. J. Pharm. Biopharm. 58, 51-59. https://doi.org/10.1016/j.ejpb.2004.03.006
피인용 문헌
- Quality by design: understanding the formulation variables and optimization of metformin hydrochloride 750 mg sustained release tablet by Box–Behnken design vol.42, pp.4, 2012, https://doi.org/10.1007/s40005-012-0032-5
- Development and Evaluation of Compression Coating Gastro-Floating Tablet of Alfuzosin Hydrochloride for Zero-Order Controlled Release vol.19, pp.7, 2018, https://doi.org/10.1208/s12249-018-1168-z